Xeldrin 40 mg/vial (IV Injection)

40 mg vial: ৳ 90.00

Medicine Details

Category	Details
Generic	Omeprazole
Company	Aci limited
Also available as	Xeldrin 10 mg capsule Xeldrin 20 mg capsule Xeldrin 40 mg capsule

Indications

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Pharmacology

Omeprazole, a substituted benzimidazole, is an inhibitor of gastric acid secretion. It inhibits gastric acid secretion by blocking hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system in the gastric parietal cell. After oral administration, the onset of the antisecretory effect occurs within one hour, with the maximum effect occurring within two hours and inhibition of secretion lasts up to 72 hours. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days.

Dosage

20 mg once daily for 4 weeks in duodenal ulceration
8 weeks in gastric ulceration
maintenance dose for recurrent duodenal ulcer, 20 mg once daily
in prevention of relapse in duodenal ulcer, 10-20 mg daily
40 mg once daily has been given for 8 weeks in gastro-esophageal reflux disease
refractory to other treatment; maintenance dose is 20 mg once daily
10-20 mg daily (Long-term management of acid reflux disease)
10-20 mg once daily for 2-4 weeks (Acid-related dyspepsia)
40 mg on the preceding evening, then 40 mg 2-6 hours before surgery (Prophylaxis of acid aspiration)
Initially 60 mg once daily for Zollinger-Ellison syndrome
20 mg twice daily in association with antimicrobial agents for Helicobacter pylori-induced peptic ulcer

Administration

Omeprazole IV injection should be given as a slow intravenous injection. The solution for IV injection should be used within 4 hours of reconstitution. Omeprazole IV infusion should be given as an intravenous infusion over a period of 20-30 minutes or more. The reconstituted solution should not be mixed or co-administered in the same infusion set with any other drug.

Interaction

Due to the decreased intragastric acidity, the absorption of ketoconazole may be reduced during Xeldrin treatment. Xeldrin is metabolized in the liver through cytochrome P450, which can delay the elimination of diazepam, phenytoin, and warfarin. Monitoring of patients receiving warfarin or phenytoin is recommended. Plasma concentrations of Xeldrin and clarithromycin are increased during concomitant administration. No evidence of an interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxycillin, or antacids.

Contraindications

Omeprazole is contraindicated in patients with known hypersensitivity to it. When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with omeprazole is instituted.

Side Effects

Skin rash, urticaria and pruritus
photosensitivity, bullous eruption, erythema multiforme, angioedema and alopecia
Diarrhoea and headache
constipation, nausea/vomiting, flatulence and abdominal pain
Dry mouth, stomatitis and candidiasis
Paraesthesia
Dizziness, light headedness and feeling faint
Somnolence, insomnia and vertigo
Reversible mental confusion, agitation, depression and hallucinations
Arthritic and myalgic symptoms
blurred vision, taste disturbance, peripheral oedema, increased sweating, gynaecomastia, leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, anaphylactic shock, malaise, fever
Increases in liver enzymes

Pregnancy & Lactation

Results from three prospective epidemiological studies indicate no adverse effects of Omeprazole on pregnancy or on the health of the fetus/newborn child. Omeprazole can be used during pregnancy.

Precautions & Warnings

Avoid concomitant use of clopidogrel and Xeldrin
Observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis- related fractures
Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with Xeldrin
Concomitant use of PPIs with methotrexate may lead to methotrexate toxicities

Therapeutic Class

Proton Pump Inhibitor

Storage Conditions

Keep in a dry place away from light and heat. Keep out of the reach of children.